Research Article
Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia
Table 1
Analysis on the basic features and coagulation index of HAML and non-HAML patients.
| | | HAML (n = 76) | Non-HAML (n = 648) | value |
| | Clinical characteristics | | | | | Sex (n) | | | | | Male | 40 | 410 | 0.049 | | Female | 36 | 238 | | | Age (mean) | 54 | 47 | 0.193 | | WBC (×109//L) | 181.890 ± 92.15 | 21.221 ± 15.971 | ＜0.005 | | PLT (×109//L) | 60.07 ± 71.101 | 63.97 ± 73.324 | ＜0.005 | | HGB (g/L) | 72.730 ± 26.342 | 77.800 ± 25.342 | 0.164 | | RBC (×1012//L) | 2.300 ± 1.033 | 3.261 ± 11.937 | 0.5115 | | Coagulation index | | | | | PT (s) | 17.133 ± 12.860 | 14.100 ± 8.940 | ＜0.005 | | FIB (mg/dL) | 322.741 ± 118.92 | 340.147 ± 171.510 | ＜0.005 | | APTT (s) | 34.139 ± 12.74 | 33.610 ± 6.101 | 0.721 | | DD (ng/mL) | 3849.276 ± 6742.661 | 1329.32 ± 1811.171 | ＜0.005 | | TT (s) | 13.291 ± 13.782 | 14.052 ± 9.460 | 0.579 | | Immune classification | | | | | CD117+ | 32.8% | 19.7% | ＜0.005 | | CD13+ | 21.3% | 20.8% | 0.312 | | HLADR | 23.1% | 22.1% | 0.479 | | CD38+ | 17.9% | 18.2% | 0.092 | | Gene mutation | | | | | FLT3-ITD | 24.3% | 19.1% | ＜0.005 | | CEBPA | 8.1% | 11.6% | ＜0.005 | | C-kit/D816 | 9.2% | 9.4% | 0.213 | | Cytogenetic prognosis | | | | | Good | 7.9% | 9.5% | 0.1893 | | Poor | 19.2% | 7.0% | ＜0.005 | | Complication | | | | | Respiratory failure | 33.3% | 23.6% | ＜0.005 | | Intracranial hemorrhage | 64,1% | 33.0% | ＜0.005 | | Heart failure | 19.2% | 18.7% | 0.942 | | Infection | 71.8% | 67.5% | ＜0.005 |
|
|
HAML: hyperleukocytic acute myeloma leukemia; WBC: white blood cell; PLT: platelet; Hb: hemoglobin; PT: prothrombin time; FIB: fibrinogen; APTT: activated partial thromboplastin time; DD: D-dimer; TT: thrombin time; values were calculated using the univariate Cox proportional-hazard model. |
